PHARMACOLOGICAL TREATMENT OF TYPE 2 DIABETES

REFERENCES

• Lebovitz HE. Clinician's manual on insulin resistance. 69 pp. Science Press, 2002.
   Google Scholar
• Report of the Expert Committee on the Diagnosis and Classifi-cation of Diabetes Mellitus. - American Diabetes Association. Clinical Practice Recommendations 2003. Diabetes Care 26 (Suppl 1): 5–20, 2003.
   Google Scholar
• Gerich JE. Contributions of insulin-resistance and insulin-se-cretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 78:447–456, 2003.
   PubMed Web of Science ®Google Scholar
• Hermans MP, Amoussou-Guenou 1(D. La résistance insuline en tant que facteur de risque cardio-vasculaire. Louvain Med 122: S268–S271, 2003.
   Google Scholar
• Eschwege E, Balkau B. [Metabolic syndrome or insulin resistance syndrome. Recent epidemiological data] [Article in French] . Ann Endocrinol (Paris) 64 ( Suppl):S32-36, 2003.
   Web of Science ®Google Scholar
• Ford ES, Giles WH. A comparison of the prevalence of the me-tabolic syndrome using two proposed definitions. Diabetes Care 26:575–581, 2003.
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S. Befroy D, Garcia R, Shulman GI. Impaired mitochondria' activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 350:664–671, 2004.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Cull CA, Stratton JIM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent di-abetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15:297-303, 1998.
   PubMed Web of Science ®Google Scholar
• Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15:290–296, 1998.
   PubMed Web of Science ®Google Scholar
• Chehade IM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 60:95–113, 2000.
   PubMed Web of Science ®Google Scholar
• Alberti KGM M, Gries FA, Jervell J, Krans HMJ for the European NIDDM Policy Group. A Desktop Guide for the Management of Non-Insulin Dependent Diabetes Mellitus (NIDDM): an Update. Diabetic Medicine 899–909, 1994.
   Web of Science ®Google Scholar
• White JR. The pharmacologic management of patients with type II diabetes mellitus in the era of new oral agents and insulin analogs. Annual Review of Diabetes 1997, 135–142, 1997.
   Google Scholar
• Turner RC, Cull CA, Frighi V. Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple thera-pies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 281:2005–2012, 1999.
   PubMed Web of Science ®Google Scholar
• Gin H, Rigalleau V. Oral antidiabetic polychemotherapy in type 2 diabetes mellitus. Diabetes Metab 2002; 28: 350–353.
   Web of Science ®Google Scholar
• Slama G. [Is it necessary to systematically treat diabetics with polytherapy at onset? Is it necessary to aim toward a precocious systematic polychemotherapy in type 2 diabetes?] [in French]. Joum Annu Diabetol Hotel-Dieu. 221–8, 2001.
   Google Scholar
• Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin. 19:635–641, 2003.
   PubMed Web of Science ®Google Scholar
• Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 49 (Suppl 2):3–6, 2000.
   PubMed Web of Science ®Google Scholar
• Harrower A. Gliclazide modified release: from once-daily admi-nistration to 24-hour blood glucose control. Metabolism 49(10 Suppl 2):7–11, 2000.
   Web of Science ®Google Scholar
• Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 25: 799–816, 2003.
   PubMed Web of Science ®Google Scholar
• Doyle ME, Egan SM. Pharmacological agents that directly mo-dulate insulin secretion. Pharmacol Rev 55:105-131, 2003.
   PubMed Web of Science ®Google Scholar
• Waldhausl W. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part I--"The pros". Horn Metab Res 28:517–521, 1996.
   Web of Science ®Google Scholar
• Heine RJ. Role of sulfonylureas in non-insulin-dependent diabe-tes mellitus: Part II--"The cons". Horm Metab Res 28:522–526, 1996.
   PubMed Web of Science ®Google Scholar
• Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29 (suppl 6): S28-S35, 2003.
   Google Scholar
• Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear U. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 51:2074–2081, 2002.
   PubMed Web of Science ®Google Scholar
• Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 348 Pt 3: 607–614, 2000.
   PubMed Web of Science ®Google Scholar
• Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 20 : 925–928, 1997.
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mecha-nism of metformin action. J Clin Invest. 108:1167–1174, 2001.
   PubMed Web of Science ®Google Scholar
• Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 57:19–29, 1999.
   PubMed Web of Science ®Google Scholar
• Breuer HVV. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Then 41:421-440, 2003.
   PubMed Web of Science ®Google Scholar
• Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 108:151–163, 2000.
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention and congestive heart failure. A Consensus Statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941–2948, 2003.
   PubMed Web of Science ®Google Scholar
• Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140: 5060-5065? 1999.
   PubMed Web of Science ®Google Scholar
• Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. - Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134 : 61–71, 2001.
   PubMed Web of Science ®Google Scholar
• Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406? 2004.
   PubMed Web of Science ®Google Scholar
• Sewter C, Vidal-Puig A. PPARy and the thiazolidinediones: molecular basis for a treatment of "Syndrome X" ? Diabetes, Obesity and Metabolism 2002; 4: 239–248.
   Web of Science ®Google Scholar
• Solomon CG. Reducing cardiovascular risk in type 2 diabetes. N Eng J Med 2003; 348: 457–459.
   PubMed Web of Science ®Google Scholar
• Stumvoll M. Thiazolidinediones -- some recent developments. Expert Opin Investig Drugs 12:1179–1187, 2003.
   PubMed Web of Science ®Google Scholar
• Theuma P, Fonseca VA.- Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Curr Diab Rep. 3: 248–254., 2003.
   Google Scholar
• Yki-Jarvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 18 Suppl 3:S77-81, 2002.
   Google Scholar
• Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 24:758–767, 2001.
   PubMed Web of Science ®Google Scholar
• DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 289:2254–2264, 2003.
   PubMed Web of Science ®Google Scholar